Cargando…

Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL

BACKGROUND: The ExoDx Prostate(IntelliScore) (EPI) test is a non-invasive risk assessment tool for detection of high-grade prostate cancer (HGPC) that informs whether to proceed with prostate biopsy. We sought to assess the impact of EPI on the decision to biopsy in a real-world clinical setting. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tutrone, Ronald, Donovan, Michael J., Torkler, Phillipp, Tadigotla, Vasisht, McLain, Tom, Noerholm, Mikkel, Skog, Johan, McKiernan, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655505/ https://www.ncbi.nlm.nih.gov/pubmed/32382078 http://dx.doi.org/10.1038/s41391-020-0237-z

Ejemplares similares

Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies
por: Margolis, Erik, et al.
Publicado: (2021)

Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome
por: Kretschmer, Alexander, et al.
Publicado: (2022)

ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis
por: Tutrone, Ronald, et al.
Publicado: (2023)

A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy
por: McKiernan, James, et al.
Publicado: (2020)

IntelliPy: a GUI for analyzing IntelliCage data
por: Ruffini, Nicolas, et al.
Publicado: (2021)

Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy
por: Kretschmer, Alexander, et al.
Publicado: (2022)

IntelliJ IDEA Essentials
por: Krochmalski, Jaroslaw
Publicado: (2014)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Inflammatory gene expression signatures in idiopathic intracranial hypertension: possible implications in microgravity-induced ICP elevation
por: Zanello, Susana B., et al.
Publicado: (2018)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients
por: Castellanos-Rizaldos, Elena, et al.
Publicado: (2019)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Windows 2000 group policy, profiles, and IntelliMirror /
por: Moskowitz, Jeremy
Publicado: (2001)

SAI Intelligent Systems Conference (IntelliSys) 2015
por: Bi, Yaxin, et al.
Publicado: (2016)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
por: Lee, Seung Hwan, et al.
Publicado: (2011)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml(-1) and 10.1–20.0 ng ml(-1): a multicenter study
por: Lin, Yu-Rong, et al.
Publicado: (2015)

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL
por: Hinev, Alexander I., et al.
Publicado: (2012)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
por: Johnson, Michael H., et al.
Publicado: (2015)

The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy
por: Shaida, Nadeem, et al.
Publicado: (2009)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
por: Busato, W. F. S., et al.
Publicado: (2015)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

PyMICE: APython library for analysis of IntelliCage data
por: Dzik, Jakub M., et al.
Publicado: (2017)

Development of an IntelliCage-based cognitive bias test for mice
por: Kahnau, Pia, et al.
Publicado: (2023)

A new basal promoter element recognized by RNA polymerase core enzyme
por: Yuzenkova, Yulia, et al.
Publicado: (2011)

Factor-independent transcription pausing caused by recognition of the RNA–DNA hybrid sequence
por: Bochkareva, Aleksandra, et al.
Publicado: (2012)

The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
por: Adegun, Patrick Temi, et al.
Publicado: (2015)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
por: Vukovic, I., et al.
Publicado: (2017)

Correlation of Serum Androgens and Pituitary Hormone Levels with Serum PSA Less Than 2.5 NG/ML
por: Sofikerim, Mustafa, et al.
Publicado: (2007)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL
por: Wang, Zhi-bing, et al.
Publicado: (2021)

Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy
por: Wu, Qiang, et al.
Publicado: (2021)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Clinical Significance of Free-to-Total Prostate-Specific Antigen (PSA) Ratio in Advanced Prostate Cancer Patients with PSA Less than 0.1 ng/ml after Hormone Treatment
por: Kim, Dae Il, et al.
Publicado: (2012)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml(−1)
por: Tan, Lincoln GL, et al.
Publicado: (2017)

Towards a computational model of learning and social interactions of mice in IntelliCage
por: Kowalski, Jakub M, et al.
Publicado: (2013)

IntelliCare: An Eclectic, Skills-Based App Suite for the Treatment of Depression and Anxiety
por: Mohr, David C, et al.
Publicado: (2017)

The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria
por: Ezenwa, E.V., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_092971vr7265079eo28vvgek8g